Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2797-2803

  Mortimer, J E ^a   Dehdashti, F ^a   Siegel, B A ^a   Trinkaus, K ^a   Katzenellenbogen, J A ^a   Welch, M J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG RESPONSE; DRUG UPTAKE; FEMALE; HORMONE RESPONSE; HUMAN; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0035367157     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2797     Document Type: Article

References (29)

1. Rising levels of estrogen receptor in breast cancer over 2 decades
2. Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer
3. Physician characteristics: Do they influence the evaluation and treatment of breast cancer in older women?
4. The lack of relationship between estrogen receptor status and response to chemotherapy
5. Estrogen receptor status and response to polychemotherapy in advanced breast cancer
6. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women: Clinical correlation on 547 patients
7. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients
8. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
9. Bone scan flare predicts successful systemic therapy for bone metastases
10. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer
11. The flare phenomenon: Far from fair and square
12. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: A possible model for tamoxifen tumour flare
13. Up-regulation of estrogen receptor by tamoxifen in human breast cancer
14. Fluorodeoxyglucose cell incorporation as an index of cell proliferation: Evaluation of accuracy in cell culture
15. PET in breast cancer
16. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
17. 18F]-fluorodeoxy-D-glucose to predict response of breast cancer to primary chemotherapy
18. Breast cancer: PET imaging of estrogen receptors
19. 18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy
20. PET assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy
21. 18F]fluoro-D-glucose by a direct nucleophilic exchange on a quaternary 4-aminopyridinium resin
22. Application of robotics to radiopharmaceutical preparation: Controlled synthesis of fluorine-18 16 alpha-fluoroestradiol-17 beta
23. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer
24. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?
25. Lung tumor imaging by positron emission tomography using C-11 L-methionine
26. A tour of UnifyPow: A SAS module/macro for sample-size analysis
27. Prognostic value of hormonally induced hypercalcemia in breast cancer
28. 85Sr local kinetics